🇺🇸 FDA

Intelligence Platform

Patents

Browse 837 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11912767

EGFR × CD28 multispecific antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11910787

Rodents having a humanized TMPRSS gene

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11910788

Mouse having a humanized cluster of differentiation 47 gene

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11904017

Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hy

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11905332

Antigen-binding molecules that bind CD38 and/or CD28, and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11897945

Methods of treating allergy using anti-Bet v 1 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11896682

Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11891607

Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11884736

Antibodies which bind to glucagon-like peptide 1 receptor (GLP1R)

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11884707

Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11866502

Anti-FGFR2 antibodies and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11866503

Methods for treating inflammatory conditions of the airway or lungs by administering antag

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11866794

Cas-ready mouse embryonic stem cells and mice and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11865134

Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (ANGPTL7) inhibitor

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11850535

Methods for quantitating individual antibodies from a mixture

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11845963

HSD17B13 variants and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11845957

Models of tauopathy

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11845931

CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11844765

Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusi

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11845800

Methods for treating or preventing asthma by administering an IL-4R antagonist

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11845989

Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11834500

Bispecific antigen binding molecules that bind leptin receptor and/or GP130, and methods o

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11834485

IL-2 variants with reduced binding to IL-2 receptor alpha and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11826386

Compositions and methods for treating cancer

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted